Amendment to the Claims

The claimed invention is:

1. (Currently amended) A compound of formula (A):



(A)

or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate or solvate thereof, wherein:
X is O ~~or S~~;

R^1 is a group of the formula



~~saturated, unsaturated, or aromatic C_3-C_{20} mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S,~~ wherein R^1 can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy,
(C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, oxo, mercapto, (C_1-C_6)alkylthio, (C_1-C_6)alkoxy, (C_5-C_{10})aryl or (C_5-C_{10})heteroaryl, (C_5-C_{10})aryloxy or (C_5-C_{10})heteroaryloxy, (C_5-C_{10})ar(C_1-C_6)alkyl or (C_5-C_{10})heteroar(C_1-C_6)alkyl,

(C_5-C_{10})ar(C_1-C_6)alkoxy or (C_5-C_{10})heteroar(C_1-C_6)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C_1-C_6)alkyl, (C_1-C_6)alkylamino(C_1-C_6)alkyl, di(C_1-C_6)alkylamino(C_1-C_6)alkyl, (C_5-C_{10})heterocyclyl(C_1-C_6)alkyl, (C_1-C_6)alkyl- and di(C_1-C_6)alkylamino, cyano, nitro, carbamoyl, (C_1-C_6)alkylcarbonyl, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylaminocarbonyl, di(C_1-C_6)alkylaminocarbonyl, (C_5-C_{10})arylcarbonyl, (C_5-C_{10})aryloxycarbonyl, (C_1-C_6)alkylsulfonyl, and (C_5-C_{10})arylsulfonyl;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, ~~(C_5-C_{10})heteroaryl~~, ~~(C_5-C_{10})heterocyclic~~, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, ~~(C_5-C_{10})heteroaryl O-~~, ~~(C_5-C_{10})heterocyclic O-~~, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1-6}HN$-, (C_1-C_6)alkyl HN-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[(((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, ~~(C_5-C_{10})heteroaryl-(C=O)-~~, ~~(C_5-C_{10})heterocyclic-(C=O)-~~, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, ~~(C_5-C_{10})heteroaryl-NH-(C=O)-~~, ~~(C_5-C_{10})heterocyclic-NH-(C=O)-~~, (C_3-C_{10})cycloalkyl-NH-(C=O)- and (C_1-C_6)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, ~~heteroaryl, heterocyclic~~, cycloalkyl, alkoxy, phenoxy, amino of R^3 is optionally substituted by at least one substituent independently selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkyl, halo, H_2N-, $Ph(CH_2)_{1-6}HN$-, and (C_1-C_6)alkylHN-;

s is an integer from one to five; and

R^4 is selected from the group consisting of: hydrogen, halo, halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, ~~(C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic~~, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy,

~~$(C_5$-$C_{10})$heteroaryl-O-, $(C_5$-$C_{10})$heterocyclic-O-~~, $(C_3$-$C_{10})$cycloalkyl-O-, $(C_1$-$C_6)$alkyl-S-, $(C_1$-$C_6)$alkyl-SO_2-, $(C_1$-$C_6)$alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1-6}NH$-, alkylNH-, $(C_1$-$C_6)$alkylamino, $[(C_1$-$C_6)alkyl]_2$-amino, $(C_1$-$C_6)$alkyl-SO_2-NH-, amino(C=O)-, aminoSO_2-, $(C_1$-$C_6)$alkyl-(C=O)-NH-, $(C_1$-$C_6)$alkyl-(C=O)-$((C_1$-$C_6)$alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-$((C_1$-$C_6)$alkyl)-N]-, $(C_1$-$C_6)$alkyl-(C=O)-, phenyl-(C=O)-, ~~$(C_5$-$C_{10})$heteroaryl-(C=O)-, $(C_5$-$C_{10})$heterocyclic-(C=O)-~~, cycloalkyl-(C=O)-, HO-(C=O)-, $(C_1$-$C_6)$alkyl-O-(C=O)-, $H_2N(C=O)$-, $(C_1$-$C_6)$alkyl-NH-(C=O)-, $((C_1$-$C_6)alkyl)_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-$((C_1$-$C_6)$alkyl)-N]-(C=O)-, ~~$(C_5$-$C_{10})$heteroaryl-NH-(C=O)-, $(C_5$-$C_{10})$heterocyclic-NH-(C=O)-~~, $(C_3$-$C_{10})$cycloalkyl-NH-(C=O)- and $(C_1$-$C_6)$alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, ~~heteroaryl, heterocyclic~~, cycloalkyl, alkoxy, phenoxy, and amino of R^4 is optionally substituted by at least one substituent independently selected from the group consisting of $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, halo$(C_1$-$C_6)$alkyl, halo, H_2N-, $Ph(CH_2)_{1-6}$-NH-, and $(C_1$-$C_6)$alkylNH-.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Currently Amended) A compound of claim 1, wherein ~~X is O~~; s is one to two; R^3 is hydrogen or $(C_1$-$C_6)$alkyl; and R^4 is H, $(C_1$-$C_6)$alkyl, or $(C_3$-$C_{10})$cycloalkyl.

10. (Cancelled)

11. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

12. (Cancelled)

13. (Cancelled)

14. (New) A compound 6-[3-(6-Methyl-pyridin-2-yl)-isoxazol-4-yl]-quinoxaline or a pharmaceutically acceptable salt thereof.

15. (New) A pharmaceutical composition comprising 6-[3-(6-Methyl-pyridin-2-yl)-isoxazol-4-yl]-quinoxaline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.